SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

Home・Elenco Azioni・Galapagos NV
Search

Galapagos NV

Chiusa

SettoreSettore sanitario

23.52 -0.84

Vendi

Aggiornamento del prezzo 15 mag 2026, 07:43 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.32

Massimo

23.62

Metriche Chiave

By Trading Economics

Entrata

-769M

14M

Vendite

-894M

6.5M

P/E

Media del settore

3.182

51.415

EPS

11.9

Margine di Profitto

214.257

Dipendenti

704

EBITDA

-813M

-65M

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

+7.35% upside

Dividendi

By Dow Jones

Utili prossimi

10 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-41M

1.6B

Apertura precedente

24.36

Chiusura precedente

23.52

Notizie sul Sentiment di mercato

By Acuity

40%

60%

127 / 345 Classifica in Healthcare

Galapagos NV Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mar 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

LeggI

23 mar 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

LeggI

24 mar 2026, 18:00 UTC

Acquisizioni, Fusioni, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

LeggI

24 mar 2026, 14:25 UTC

Acquisizioni, Fusioni, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

LeggI

24 mar 2026, 13:35 UTC

Acquisizioni, Fusioni, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

LeggI

24 mar 2026, 12:03 UTC

Acquisizioni, Fusioni, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. 'Immune Reset' Is Key to Future Gains. -- Barrons.com

DJ

LeggI

23 mar 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

LeggI

23 mar 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

LeggI

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

LeggI

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

LeggI

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

LeggI

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

LeggI

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

LeggI

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

LeggI

Confronto tra pari

Modifica del prezzo

Galapagos NV Previsione

Obiettivo di Prezzo

By TipRanks

7.35% in crescita

Previsioni per 12 mesi

Media 25.85 EUR  7.35%

Alto 30 EUR

Basso 22 EUR

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Galapagos NV - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

4 ratings

0

Acquista

2

Mantieni

2

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Galapagos NV - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

127 / 345 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Altri titoli del settore

SAN

Sanofi SA

73.96

↑ +1.25%

ARGX

Argenx SE

691.6

↑ +0.03%

SHL.DE

Siemens Healthineers AG

33.51

↓-1.93%

FRE

Fresenius SE & Co KGaA

38.8

↓-0.33%

PHIA

Koninklijke Philips NV

21.75

↓-1.27%
help-icon Live chat